Case Study: a global pharmaceutical giant achieves clinical data ecosystem convergence and cost savings with GEP

U.K. Chemicals Giant saves 7% on licensing and 30% on managed services with GEP

GEP was engaged by a global pharmaceutical giant facing a significant challenge following a record-breaking merger. The customer needed to efficiently converge its clinical trial data ecosystems to realize synergies and ensure business continuity, all within a challenging timeline complicated by the COVID-19 pandemic.

GEP helped the pharmaceutical company rework its governance and implement a strategy for clinical data ecosystem convergence. This solution delivered substantial cost savings, achieving approximately 7% savings on annual licensing spend and 30% savings on annual managed services spend, while securing long-term operational benefits.

U.K. Chemicals Giant